Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals (ARWR) is a clinical-stage biopharmaceutical company developing RNA interference therapies that silence disease-causing genes. The company's news flow centers on clinical trial developments, regulatory milestones, and partnership announcements that signal progress in its genetic medicine pipeline.
Clinical development updates represent the most significant category of Arrowhead news. Phase 1, 2, and 3 trial initiations reveal which therapeutic programs are advancing through human testing. Trial results demonstrate whether investigational RNAi therapeutics achieve target gene knockdown and clinical efficacy in patients. These updates often include pharmacodynamic data showing reductions in disease-related proteins, providing concrete evidence of biological activity.
Regulatory decisions from the FDA and international agencies mark critical validation points. Breakthrough therapy designations indicate regulators recognize substantial improvement potential over existing treatments. Investigational New Drug (IND) application clearances and Clinical Trial Authorization (CTA) approvals enable new studies to begin. Orphan drug designations for rare disease programs provide development incentives and potential market exclusivity.
Partnership announcements and collaborations with larger pharmaceutical companies signal external validation of Arrowhead's TRiM platform technology. These agreements typically involve upfront payments, development milestones, and royalty structures tied to commercial success. Partnership news often specifies which disease targets the collaboration will address and how responsibilities are divided between companies.
Corporate developments including financing activities, patent grants, and inducement grants provide context on the company's operational capacity. Public offerings and debt transactions affect the capital available for advancing clinical programs. Patent issuances strengthen intellectual property positions around specific RNAi molecules and delivery technologies.
Track Arrowhead Pharmaceuticals news to monitor genetic medicine development, understand RNAi therapeutic progress across multiple disease areas, and follow regulatory advancements in gene silencing technologies.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its fiscal first quarter results for the period ended December 31, 2020. The company generated $21.3 million in revenue, down from $29.5 million in the same quarter of 2019. Operating expenses increased to $45.4 million, leading to a net loss of $20.7 million or $0.20 per share, compared to a loss of $2.7 million or $0.03 per share in the previous year. The firm is advancing its clinical pipeline with ongoing trials and collaborations, including a significant agreement with Takeda.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an Investigational New Drug Application to the FDA for a Phase 2b study of ARO-ANG3, targeting mixed dyslipidemia. The trial aims to evaluate the safety and efficacy of the RNA interference therapeutic, focusing on reducing triglycerides and LDL cholesterol. The upcoming AROANG3-2001 study will enroll 180 participants to establish an effective dosing regimen. CMO Javier San Martin emphasized the need for new therapies in cardiovascular care, highlighting promising preliminary clinical data.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a webcast and conference call scheduled for February 4, 2021, at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ending December 31, 2020. Investors can access the live audio webcast on the Company's website. A replay will be available for 90 days post-call. Arrowhead specializes in developing RNA interference-based therapeutics targeting intractable diseases through innovative gene silencing techniques.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced inducement grants for 27 new employees, approved on December 4, 2020. The grants include options to purchase 145,000 shares at a strike price of $65.29 and the potential for 96,000 restricted stock units (RSUs). These grants are outside the stockholder-approved equity incentive plans and will vest over four years. Arrowhead focuses on RNA interference therapies targeting intractable diseases, leveraging gene silencing to effectively treat conditions.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in key upcoming events. The Piper Sandler 32nd Annual Virtual Healthcare Conference occurs from December 1-3, 2020, featuring a presentation by CEO Chris Anzalone on December 2. Additionally, at the 20th Gordon L. Snider Critical Issues Workshop on December 12, James Hamilton, M.D., will discuss Arrowhead’s gene silencing approach for liver disease in Alpha-1 antitrypsin deficiency. Webcast links and materials are accessible on the company's Events and Presentations page.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that the collaboration and license agreement with Takeda Pharmaceutical Company Limited has officially closed. This closing was contingent upon review under U.S. antitrust laws, including the Hart-Scott-Rodino Act. Arrowhead focuses on developing RNA interference-based therapies to treat intractable diseases, leveraging its portfolio of RNA chemistries for gene silencing.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported fiscal year 2020 results showing a significant revenue decline to $87.99 million from $168.80 million in 2019. The operating loss widened to $93.16 million, with a net loss of $84.55 million, translating to a diluted loss per share of $0.84. However, the company received a $20 million milestone from Amgen and achieved a strategic partnership with Takeda, including $300 million upfront and up to $740 million in milestones. Cash resources increased to $452.98 million, bolstering its financial position despite operating challenges.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced promising clinical data from its cardiometabolic pipeline at the AHA Scientific Sessions 2020. The company's investigational products, ARO-ANG3 and ARO-APOC3, showed strong responses in lipid parameters, addressing persistent cardiovascular risks. Notable presentations include pharmacodynamic effects targeting hypercholesterolemia and hypertriglyceridemia. Webinars on November 18 and 19 will further discuss these findings and future plans. These advancements position Arrowhead favorably in the competitive landscape of cardiovascular therapeutics.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announces positive interim results from its Phase 2 study AROAAT2002, evaluating ARO-AAT for treating alpha-1 antitrypsin deficiency (AATD). Patients receiving three doses showed significant reductions in the disease-causing Z-AAT protein, with serum reductions of 86-93% and liver reductions up to 95%. Improvements were noted in liver health biomarkers. The study indicates potential for accelerated regulatory discussions as further patient data is expected in the coming months.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to participate in significant upcoming medical events. From November 13-16, 2020, at the Liver Meeting Digital Experience, they will present findings on ARO-AAT's effectiveness in reducing Z-AAT protein in patients with liver disease. At the AHA Scientific Sessions (November 13-17, 2020), the company will showcase multiple studies, including ARO-ANG3 and ARO-APOC3, targeting hypercholesterolemia and hypertriglyceridemia. CEO Chris Anzalone will engage in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020.
FAQ
What is the current stock price of Arrowhead Pharma (ARWR)?
What is the market cap of Arrowhead Pharma (ARWR)?
